Publicacións en colaboración con investigadores/as de Hospital Universitario Son Espases (14)

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care

  3. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

  4. SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients

    Medicina Intensiva

  5. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Critical Care, Vol. 25, Núm. 1

2020

  1. SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 67, Núm. 7, pp. 391-399

2016

  1. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

2013

  1. Survival of hematological patients after discharge from the intensive care unit: A prospective observational study

    Critical Care, Vol. 17, Núm. 6

2007

  1. Risk factors for candidaemia in critically ill patients: A prospective surveillance study

    Mycoses, Vol. 50, Núm. 4, pp. 302-310

1995

  1. METODO ALTERNATIVO PARA EL CALCULO MATEMATICO DE LA DOSIS LETAL 50/30 PARA IRRADIACION CORPORAL TOTAL CON RADIACION GAMMA EN MODELO ANIMAL EXPERIMENTAL

    Oncologia, Vol. 18, Núm. 10, pp. 48-53

1991

  1. CARCINOMA AVANZADO DE CERVIX. TELECOBALTOTERAPIA

    Oncologia, Vol. 14, Núm. 7, pp. 347-352